Literature DB >> 24932437

Questioning the Use of PEGylation for Drug Delivery.

Johan J F Verhoef1, Thomas J Anchordoquy2.   

Abstract

Polyethylene glycol (PEG) is widely utilized in drug delivery and nanotechnology due to its reported "stealth" properties and biocompatibility. It is generally thought that PEGylation allows particulate delivery systems and biomaterials to evade the immune system and thereby prolong circulation lifetimes. However, numerous studies over the past decade have demonstrated that PEGylation causes significant reductions in drug delivery, including enhanced serum protein binding, reduced uptake by target cells, and the elicitation of an immune response that facilitates clearance in vivo. This report reviews some of the extensive literature documenting the detrimental effects of PEGylation, and thereby questions the wisdom behind employing this strategy in drug development.

Entities:  

Keywords:  DNA; PEG; RNA; drug delivery; immunogenicity; polyethylene glycol; stealth; transfection

Year:  2013        PMID: 24932437      PMCID: PMC4051498          DOI: 10.1007/s13346-013-0176-5

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  61 in total

1.  PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner.

Authors:  Tatsuhiro Ishida; Xinyu Wang; Taro Shimizu; Kosuke Nawata; Hiroshi Kiwada
Journal:  J Control Release       Date:  2007-05-21       Impact factor: 9.776

2.  Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.

Authors:  XinYu Wang; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  J Control Release       Date:  2007-02-24       Impact factor: 9.776

3.  Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead.

Authors:  S M Moghimi; A J Andersen; S H Hashemi; B Lettiero; D Ahmadvand; A C Hunter; T L Andresen; I Hamad; J Szebeni
Journal:  J Control Release       Date:  2010-04-11       Impact factor: 9.776

4.  Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding.

Authors:  Nancy Dos Santos; Christine Allen; Anne-Marie Doppen; Malathi Anantha; Kelly A K Cox; Ryan C Gallagher; Goran Karlsson; Katarina Edwards; Gail Kenner; Lacey Samuels; Murray S Webb; Marcel B Bally
Journal:  Biochim Biophys Acta       Date:  2007-01-03

5.  Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression.

Authors:  E Ambegia; S Ansell; P Cullis; J Heyes; L Palmer; I MacLachlan
Journal:  Biochim Biophys Acta       Date:  2005-02-24

6.  Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan.

Authors:  ChunLei Li; Xi Zhao; YaJuan Wang; HanYu Yang; HaiXia Li; Huan Li; Wei Tian; Jian Yang; JingXia Cui
Journal:  Int J Pharm       Date:  2013-01-11       Impact factor: 5.875

Review 7.  Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes.

Authors:  Andrea Cerutti; Montserrat Cols; Irene Puga
Journal:  Nat Rev Immunol       Date:  2013-02       Impact factor: 53.106

8.  Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles.

Authors:  Tsutomu Ishihara; Miho Takeda; Haruka Sakamoto; Ayumi Kimoto; Chisa Kobayashi; Naoko Takasaki; Kanae Yuki; Ken-ichiro Tanaka; Mitsuko Takenaga; Rie Igarashi; Taishi Maeda; Naoki Yamakawa; Yoshinari Okamoto; Masami Otsuka; Tatsuhiro Ishida; Hiroshi Kiwada; Yutaka Mizushima; Tohru Mizushima
Journal:  Pharm Res       Date:  2009-07-25       Impact factor: 4.200

9.  Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.

Authors:  Amr S Abu Lila; Noha Essam Eldin; Masako Ichihara; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Int J Pharm       Date:  2012-08-24       Impact factor: 5.875

10.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

View more
  68 in total

1.  Vascular Accessibility of Endothelial Targeted Ferritin Nanoparticles.

Authors:  Makan Khoshnejad; Vladimir V Shuvaev; Katherine W Pulsipher; Chuanyun Dai; Elizabeth D Hood; Evguenia Arguiri; Melpo Christofidou-Solomidou; Ivan J Dmochowski; Colin F Greineder; Vladimir R Muzykantov
Journal:  Bioconjug Chem       Date:  2016-01-15       Impact factor: 4.774

2.  Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol.

Authors:  Sai Prachetan Balguri; Goutham R Adelli; Karthik Yadav Janga; Prakash Bhagav; Soumyajit Majumdar
Journal:  Int J Pharm       Date:  2017-06-17       Impact factor: 5.875

Review 3.  Watching the gorilla and questioning delivery dogma.

Authors:  Thomas J Anchordoquy; Dmitri Simberg
Journal:  J Control Release       Date:  2017-07-14       Impact factor: 9.776

Review 4.  Liquid Crystalline Phases for Enhancement of Oral Bioavailability.

Authors:  Xingwang Zhang; Wei Wu
Journal:  AAPS PharmSciTech       Date:  2021-02-22       Impact factor: 3.246

Review 5.  Unintended effects of drug carriers: Big issues of small particles.

Authors:  Hamideh Parhiz; Makan Khoshnejad; Jacob W Myerson; Elizabeth Hood; Priyal N Patel; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

Review 6.  Nanotechnology in cell replacement therapies for type 1 diabetes.

Authors:  Alexander U Ernst; Daniel T Bowers; Long-Hai Wang; Kaavian Shariati; Mitchell D Plesser; Natalie K Brown; Tigran Mehrabyan; Minglin Ma
Journal:  Adv Drug Deliv Rev       Date:  2019-02-02       Impact factor: 15.470

7.  Reducing the Visibility of the Vector/DNA Nanocomplexes to the Immune System by Elastin-Like Peptides.

Authors:  Faranak S Nouri; Xing Wang; Xuguang Chen; Arash Hatefi
Journal:  Pharm Res       Date:  2015-03-31       Impact factor: 4.200

8.  Advances in targeted nanotherapeutics: From bioconjugation to biomimicry.

Authors:  Danielle M Valcourt; Jenna Harris; Rachel S Riley; Megan Dang; Jianxin Wang; Emily S Day
Journal:  Nano Res       Date:  2018-05-17       Impact factor: 8.897

9.  Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery.

Authors:  Jamie L Betker; Dallas Jones; Christine R Childs; Karen M Helm; Kristina Terrell; Maria A Nagel; Thomas J Anchordoquy
Journal:  J Control Release       Date:  2018-07-17       Impact factor: 9.776

10.  A Cell Assay for Detecting Anti-PEG Immune Response against PEG-Modified Therapeutics.

Authors:  Taro Shimizu; Amr S Abu Lila; Mizuki Awata; Yukiyo Kubo; Yu Mima; Yosuke Hashimoto; Hidenori Ando; Keiichiro Okuhira; Yu Ishima; Tatsuhiro Ishida
Journal:  Pharm Res       Date:  2018-10-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.